Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bingham, S. J.
Right arrow Articles by Emery, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bingham, S. J.
Right arrow Articles by Emery, P.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2003; 42: 1009-1010
© 2003 British Society for Rheumatology

Letters to the Editor

Parenteral methotrexate should be given before biological therapy

S. J. Bingham, M. H. Buch, S. Lindsay, A. Pollard1, J. White1 and P. Emery

Rheumatology Research Unit, University of Leeds and
1 Rheumatology Department, Leeds General Infirmary, Leeds, UK

The first 10% of the full text of this article appears below.

Methotrexate (MTX) is the most commonly used disease-modifying agent and is considered to be the gold standard treatment for therapy of rheumatoid arthritis (RA). The British Society for Rheumatology/National Institute for Clinical Excellence guidelines stipulate that patients must have failed therapy with MTX for at least 6 months (unless limited by toxicity) in order to be considered for anti-tumour necrosis factor {alpha} therapies [1]. In many cases MTX is efficacious and in general is well tolerated [2]. However, some patients do not . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
R. K. Moitra, J. M. Ledingham, R. G. Hull, F. C. McCrae, A. L. Thomas, R. Shaban, and K. R. MacKay
Caveats to the use of parenteral methotrexate in the treatment of rheumatic disease
Rheumatology, February 1, 2005; 44(2): 256 - 257.
[Full Text] [PDF]

Home page
 Ann Rheum DisHome page
J Wegrzyn, P Adeleine, and P Miossec
Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis
Ann Rheum Dis, October 1, 2004; 63(10): 1232 - 1234.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. J. Griffin and F. Erkeller-Yuksel
Parenteral methotrexate should be given before biological therapy
Rheumatology, May 1, 2004; 43(5): 678 - 678.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
S. J. Bingham, M. H. Buch, and P. Emery
Reply: Parenteral methotrexate should be given before biological therapy
Rheumatology, May 1, 2004; 43(5): 678 - 679.
[Full Text] [PDF]